No profile data available.
Phio Pharmaceuticals Corp. (PHIO) is a healthcare company in the additional cancer treatment drugs industry, based in King of Prussia, United States, with about 6 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$8.70 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $11.37 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
Phio Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$11.37 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Lantern Pharma Inc. (LTRN), Intensity Therapeutics, Inc. (INTS), Lisata Therapeutics, Inc. (LSTA), Bolt Biotherapeutics, Inc. (BOLT).